New York, New York–(Newsfile Corp. – December 21, 2024) – Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws.
If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Why is BioAge being Investigated?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company’s lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.
During the relevant period, the company stated that azelaprag was well-tolerated in 265 individuals across eight Phase 1 clinical trials and that following the company’s IPO it was “well-equipped to advance our clinical programs[.]”
The Stock Declines as the Truth is Revealed
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The company stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested[.]”
This news caused the price of the company’s stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
What Can You Do?
If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla (NASDAQ:TSLA), Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical (NYSE:TEVA) Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Attorney advertising. Past results do not guarantee future outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233987
